Jan. 19 – Siena is at the helm of the fight against Ebola, kick off the VSV-Ebovac research that tries to analyze the immune response of one of the three Ebola vaccines recently declared by the WHO as the most promising in the fight against the terrible epidemic underway in West Africa. The project will last three years and is coordinated by Professor Donata Medaglini, on behalf of the University of Siena and Sclavus Vaccines Association (SVA). “Being able, with our research, to help eradicate a disease as devastating as Ebola is of great ethical value for us – commented Professor Medaglini – this gives a deeper meaning to our research. I think it is also important to highlight the rapid and efficient response of our scientific community in the face of a health issue of such magnitude. In Siena, we were able to network the experience gained over many years in the vaccine field, bringing together the great synergies between public and private entities that had already been put in place for the European project Aditec.” (PO / red)
The VSV-EBOVAC is one of the first eight projects that received a total fundind of 3.9 million by the Innovative Medicines Initiative (IMI), a partnership between the European Union (Horizon 2020) and the European Federation of Pharmaceutical and Industries Associations (EFPIA), under the Ebola + program. The program aims to accelerate all aspects of the development, production and use of a viable vaccine, as well as their therapeutic and diagnostic protocols.
BigItaly focusBigiItalyfocus is a daily news service offering informations and insights on the best of the italian presence in the world.
From Monday to Friday, BigItalyFocus provides an information overview, ranged from development aid to made in Italy